Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Региональная программа лечения больных первично-генерализованным и метастатическим раком молочной железы
Региональная программа лечения больных первично-генерализованным и метастатическим раком молочной железы
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Cameron RB. Malignancies of the Breast. Chap. 53 in A Lange Clinical Manual - Practical Oncology 1st Edition. Norwalk: Appleton & Lange, 1994.
2. Frei E, Teicher BA, Holden SA, Cathcart KN, Wang YY. Preclinical Studies and Clinical Correlation of the Effect of Alkylator Dose. Cancer Res 1988; 48:6417.
3. Norton L, Hortobagyi GN, Shpall EJ. Educational Book: Conceptual Issues in the High-Dose Chemotherapy of Breast Cancer. American Society of Clinical Oncology, 1995; 335–340.
4. Papahadjopoulous D, Allen TN, Gabizon A., et-al. Sterically Stabilized Liposomes: Improvement in Pharmacokinetics and Anti-Tumour Therapeutic Efficacy. PNAS 1991; 88:11460-64.
5. Martin FJ, Gabizon A, Human Pharmacokinetics of Stealth Liposomes containing Doxorubicin, J. Cell Biochem 1992; Supplement 16E:98.
6. Uziely B, Jeffers S, Isacson R, et al. Liposomal Doxorubicin: Antitumor Activity and Unique Toxicities During Two Complementary Phase I Studies. J Clin Oncol, 1995; 13(7):1777–85.
7. Keller, A. M.; Mennel, R. G.; Nabholtz, J. M.; Tendler, C. L.; et al.Phase III Trial of Pegylated Liposomal Doxorubicin (Caelyx/Doxil) for the Treatment of Patients with Advanced Breast Cancer Who Have Failed a Prior Taxane-Containing Chemotherapy Regimen. Proc. Am. Soc. Clin. Oncol., (37th Ann. Mtg., ASCO, San Francisco, CA, USA, May 12-15, 2001), Vol. 20, Pt. 1, 2001, Abstr. No. 115.
8. O'Brien N. Wigler, M. Inbar et al , Reduced cardiotoxicity and comparable efficacy in phase III trial of Pegylated Liposomal Doxorubicin (Caelyx/Doxil) vs conventional doxorubicin for first-line treatment of metaststic breast cancer Annals of Oncology, 2004, v15, p. 440-9
9. S-E Al-Batran et al.The clinical benefit of pegilated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br Jour Cancer, (2006), 1–6
10. D.Lorusso et al. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome), review article, Annals Oncol, Jan 17, 2007:1–6.
2. Frei E, Teicher BA, Holden SA, Cathcart KN, Wang YY. Preclinical Studies and Clinical Correlation of the Effect of Alkylator Dose. Cancer Res 1988; 48:6417.
3. Norton L, Hortobagyi GN, Shpall EJ. Educational Book: Conceptual Issues in the High-Dose Chemotherapy of Breast Cancer. American Society of Clinical Oncology, 1995; 335–340.
4. Papahadjopoulous D, Allen TN, Gabizon A., et-al. Sterically Stabilized Liposomes: Improvement in Pharmacokinetics and Anti-Tumour Therapeutic Efficacy. PNAS 1991; 88:11460-64.
5. Martin FJ, Gabizon A, Human Pharmacokinetics of Stealth Liposomes containing Doxorubicin, J. Cell Biochem 1992; Supplement 16E:98.
6. Uziely B, Jeffers S, Isacson R, et al. Liposomal Doxorubicin: Antitumor Activity and Unique Toxicities During Two Complementary Phase I Studies. J Clin Oncol, 1995; 13(7):1777–85.
7. Keller, A. M.; Mennel, R. G.; Nabholtz, J. M.; Tendler, C. L.; et al.Phase III Trial of Pegylated Liposomal Doxorubicin (Caelyx/Doxil) for the Treatment of Patients with Advanced Breast Cancer Who Have Failed a Prior Taxane-Containing Chemotherapy Regimen. Proc. Am. Soc. Clin. Oncol., (37th Ann. Mtg., ASCO, San Francisco, CA, USA, May 12-15, 2001), Vol. 20, Pt. 1, 2001, Abstr. No. 115.
8. O'Brien N. Wigler, M. Inbar et al , Reduced cardiotoxicity and comparable efficacy in phase III trial of Pegylated Liposomal Doxorubicin (Caelyx/Doxil) vs conventional doxorubicin for first-line treatment of metaststic breast cancer Annals of Oncology, 2004, v15, p. 440-9
9. S-E Al-Batran et al.The clinical benefit of pegilated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br Jour Cancer, (2006), 1–6
10. D.Lorusso et al. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome), review article, Annals Oncol, Jan 17, 2007:1–6.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.